Swiss cell line development firm Selexis granted TeneoBio access to its SUREtechnology Platform™ for use in developing and optimizing the cellular expression of anticancer human heavy-chain antibodies (UniAbs™) discovered using TeneoBio’s sequence-based TeneoSeek discovery platform and UniRat® human heavy-chain antibody platform.

Selexis claims its SUREtechnology platform facilitates rapid, stable, and cost-effective production of just about any recombinant protein. “We believe in the power of the Selexis SUREtechnology Platform to help TeneoBio rapidly and predictably achieve the high antibody expression levels and cell line stability that are needed for the cost-effective production of their unique multispecific antibody candidates,” commented Yemi Onakunle, Ph.D., vp for business development and licensing at Selexis.

TeneoBio is exploiting a proprietary sequence-based discovery approach using next-generation sequencing, bioinformatics, and high-throughput screening to identify lead UniAbs against cancer and  autoimmune and infectious diseases. The firm’s preclinical pipeline includes mono-, bi-, and trispecific candidates against multiple myeloma, lymphoma, human immunodeficiency virus (HIV), and immune checkpoint inhibitors.

Commenting on the service agreement with Selexis, Omid Vafa, Ph.D., CBO at TeneoBio, stated, “This is the first of several TeneoBio bi- and multispecific UniAb candidates that leverages our unique T-cell redirection platform to target liquid and solid tumors.”

Within the last month, TeneoBio inked a license agreement with Poseida Therapeutics, giving the latter commercial rights to use its single-domain, human heavy-chain-only antibodies (UniDabs™) in chimeric antigen receptor (CAR) T-cell therapy.

In May, Selexis opened its new corporate headquarters and laboratory facilities for SUREtechnology Platform R&D, in Geneva, Switzerland. In the same month, the firm signed separate SUREtechnology Platform agreements with Merck KGaA and with OSE Therapeutics. 

Previous articlePeptiDream Inks Peptide Discovery Platform License with Shionogi
Next articleImmunotherapy Response Predicted by DNA Repair Deficiencies